PT  - JOURNAL ARTICLE
AU  - Derrek A. Heuveling
AU  - Gerard W.M. Visser
AU  - Marian Baclayon
AU  - Wouter H. Roos
AU  - Gijs J.L. Wuite
AU  - Otto S. Hoekstra
AU  - C. René Leemans
AU  - Remco de Bree
AU  - Guus A.M.S. van Dongen
TI  - <sup>89</sup>Zr-Nanocolloidal Albumin–Based PET/CT Lymphoscintigraphy for Sentinel Node Detection in Head and Neck Cancer: Preclinical Results
AID  - 10.2967/jnumed.111.089557
DP  - 2011 Oct 01
TA  - Journal of Nuclear Medicine
PG  - 1580--1584
VI  - 52
IP  - 10
4099  - http://jnm.snmjournals.org/content/52/10/1580.short
4100  - http://jnm.snmjournals.org/content/52/10/1580.full
SO  - J Nucl Med2011 Oct 01; 52
AB  - Identifying sentinel nodes near the primary tumor remains a problem in, for example, head and neck cancer because of the limited resolution of current lymphoscintigraphic imaging when using 99mTc-nanocolloidal albumin. This study describes the development and evaluation of a nanocolloidal albumin–based tracer specifically dedicated for high-resolution PET detection. Methods: 89Zr was coupled to nanocolloidal albumin via the bifunctional chelate p-isothiocyanatobenzyldesferrioxamine B. Quality control tests, including particle size measurements, and in vivo biodistribution and imaging experiments in a rabbit lymphogenic metastasis model were performed. Results: Coupling of 89Zr to nanocolloidal albumin appeared to be efficient, resulting in a stable product with a radiochemical purity greater than 95%, without affecting the particle size. PET showed distinguished uptake of 89Zr-nanocolloidal albumin in the sentinel nodes, with visualization of lymphatic vessels, and with a biodistribution comparable to 99mTc-nanocolloidal albumin. Conclusion: 89Zr-nanocolloidal albumin is a promising tracer for sentinel node detection by PET.